160 related articles for article (PubMed ID: 34809599)
1. Survival impact of additional chemotherapy after adjuvant concurrent chemoradiation in patients with early cervical cancer who underwent radical hysterectomy.
Kim SI; Kim JY; Wee CW; Lee M; Kim HS; Chung HH; Lee TS; Jeon HW; Park NH; Song YS; Kim TH
BMC Cancer; 2021 Nov; 21(1):1260. PubMed ID: 34809599
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant chemotherapy versus concurrent chemoradiotherapy for high-risk cervical cancer after radical hysterectomy and systematic lymphadenectomy.
Takekuma M; Kasamatsu Y; Kado N; Kuji S; Tanaka A; Takahashi N; Abe M; Hirashima Y
Int J Clin Oncol; 2016 Aug; 21(4):741-747. PubMed ID: 26857458
[TBL] [Abstract][Full Text] [Related]
3. The long-term efficacy of neoadjuvant chemotherapy followed by radical hysterectomy compared with radical surgery alone or concurrent chemoradiotherapy on locally advanced-stage cervical cancer.
Yin M; Zhao F; Lou G; Zhang H; Sun M; Li C; Hou Y; Li X; Meng F; Chen X
Int J Gynecol Cancer; 2011 Jan; 21(1):92-9. PubMed ID: 21330834
[TBL] [Abstract][Full Text] [Related]
4. Clinical Role of Adjuvant Chemotherapy after Radical Hysterectomy for FIGO Stage IB-IIA Cervical Cancer: Comparison with Adjuvant RT/CCRT Using Inverse-Probability-of-Treatment Weighting.
Jung PS; Kim DY; Lee SW; Park JY; Suh DS; Kim JH; Kim YM; Kim YT; Nam JH
PLoS One; 2015; 10(7):e0132298. PubMed ID: 26176626
[TBL] [Abstract][Full Text] [Related]
5. Platinum-based combination chemotherapy vs. weekly cisplatin during adjuvant CCRT in early cervical cancer with pelvic LN metastasis.
Lee YY; Park W; Huh SJ; Yoon A; Park JY; Choi CH; Kim TJ; Lee JW; Kim BG; Bae DS
Anticancer Res; 2013 Oct; 33(10):4675-81. PubMed ID: 24123048
[TBL] [Abstract][Full Text] [Related]
6. Impact of the addition of concurrent chemotherapy to pelvic radiotherapy in surgically treated stage IB1-IIB cervical cancer patients with intermediate-risk or high-risk factors: a 13-year experience.
Okazawa M; Mabuchi S; Isohashi F; Suzuki O; Yoshioka Y; Sasano T; Ohta Y; Kamiura S; Ogawa K; Kimura T
Int J Gynecol Cancer; 2013 Mar; 23(3):567-75. PubMed ID: 23385284
[TBL] [Abstract][Full Text] [Related]
7. Comparison of adjuvant therapy for node-positive clinical stage IB-IIB cervical cancer: Systemic chemotherapy versus pelvic irradiation.
Matsuo K; Shimada M; Aoki Y; Sakamoto M; Takeshima N; Fujiwara H; Matsumoto T; Mikami M; Sugiyama T
Int J Cancer; 2017 Sep; 141(5):1042-1051. PubMed ID: 28524247
[TBL] [Abstract][Full Text] [Related]
8. [Results of different postoperative adjuvant therapies for stage Ib-IIa cervical carcinoma with risk factors].
Wen HW; Huang WP; Liu TY; Ma K; Tao X; Zhu LR; Liao QP
Zhonghua Fu Chan Ke Za Zhi; 2013 Dec; 48(12):920-4. PubMed ID: 24495686
[TBL] [Abstract][Full Text] [Related]
9. Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer.
Kokka F; Bryant A; Brockbank E; Powell M; Oram D
Cochrane Database Syst Rev; 2015 Apr; (4):CD010260. PubMed ID: 25847525
[TBL] [Abstract][Full Text] [Related]
10. Weekly versus triweekly cisplatin-alone adjuvant chemoradiotherapy after radical hysterectomy for stages IB-IIA cervical cancer with risk of recurrence.
Zhu J; Lou R; Ji S; Wu G; Chen Q; Hu Q; Zhao Y; Cai D; Gu K
Anticancer Drugs; 2021 Feb; 32(2):203-209. PubMed ID: 33186140
[TBL] [Abstract][Full Text] [Related]
11. Postoperative adjuvant concurrent chemoradiotherapy improves survival rates for high-risk, early stage cervical cancer patients.
Ryu HS; Chun M; Chang KH; Chang HJ; Lee JP
Gynecol Oncol; 2005 Feb; 96(2):490-5. PubMed ID: 15661240
[TBL] [Abstract][Full Text] [Related]
12. Analysis of Prognostic Factors Affecting the Outcome of Stage IB-IIB Cervical Cancer Treated by Radical Hysterectomy and Pelvic Lymphadenectomy.
Xia X; Xu H; Wang Z; Liu R; Hu T; Li S
Am J Clin Oncol; 2016 Dec; 39(6):604-608. PubMed ID: 24937635
[TBL] [Abstract][Full Text] [Related]
13. Concurrent paclitaxel/cisplatin chemoradiotherapy with or without consolidation chemotherapy in high-risk early-stage cervical cancer patients following radical hysterectomy: preliminary results of a phase III randomized study.
Zhao H; Li L; Su H; Lin B; Zhang X; Xue S; Fei Z; Zhao L; Pan Q; Jin X; Xie C
Oncotarget; 2016 Oct; 7(43):70969-70978. PubMed ID: 27391158
[TBL] [Abstract][Full Text] [Related]
14. The upper limit of optimal tumor size in patients with FIGO 2018 stage IB2 cervical cancer undergoing radical hysterectomy.
Hwang WY; Kim JH; Suh DH; Kim K; No JH; Kim YB
Int J Gynecol Cancer; 2020 Jul; 30(7):975-980. PubMed ID: 32467336
[TBL] [Abstract][Full Text] [Related]
15. [Curative effect analysis of postoperative concurrent chemoradiotherapy on early-stage cervical cancer patients with intermediate-risk factors].
Tang Q; Tu YQ; Chen JH; Lyu XJ; Yan DD
Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):462-466. PubMed ID: 29936774
[No Abstract] [Full Text] [Related]
16. Adjuvant chemotherapy after concurrent chemoradiation for locally advanced cervical cancer.
Tangjitgamol S; Katanyoo K; Laopaiboon M; Lumbiganon P; Manusirivithaya S; Supawattanabodee B
Cochrane Database Syst Rev; 2014 Dec; 2014(12):CD010401. PubMed ID: 25470408
[TBL] [Abstract][Full Text] [Related]
17. Definite chemoradiotherapy is a competent treatment option in FIGO stage IB2 cervical cancer compared with radical surgery +/- neoadjuvant chemotherapy.
Hsieh HY; Huang JW; Lu CH; Lin JC; Wang L
J Formos Med Assoc; 2019 Jan; 118(1 Pt 1):99-108. PubMed ID: 29429800
[TBL] [Abstract][Full Text] [Related]
18. Comparison of survival outcomes between minimally invasive surgery and conventional open surgery for radical hysterectomy as primary treatment in patients with stage IB1-IIA2 cervical cancer.
Kim SI; Cho JH; Seol A; Kim YI; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS
Gynecol Oncol; 2019 Apr; 153(1):3-12. PubMed ID: 30642625
[TBL] [Abstract][Full Text] [Related]
19. Effects of Neoadjuvant Chemotherapy Plus Radical Surgery as Front Line Treatment Strategy in Patients Affected by FIGO Stage III Cervical Cancer.
Di Donato V; Schiavi MC; Ruscito I; Visentin VS; Palaia I; Marchetti C; Fischetti M; Monti M; Muzii L; Benedetti Panici P
Ann Surg Oncol; 2016 Dec; 23(Suppl 5):841-849. PubMed ID: 27678502
[TBL] [Abstract][Full Text] [Related]
20. Role of adjuvant therapy after radical hysterectomy in intermediate-risk, early-stage cervical cancer.
Cao L; Wen H; Feng Z; Han X; Zhu J; Wu X
Int J Gynecol Cancer; 2021 Jan; 31(1):52-58. PubMed ID: 33303568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
